Topic:

M&A

Latest Headlines

Latest Headlines

Neogen acquires BioLumix through purchase of outstanding stock

Neogen, the maker of food and animal safety products, acquired Ann Arbor, MI-based BioLumix through a purchase of all of the company's outstanding stock.

BD to buy CareFusion for $12.2B to become more hospital-focused

Inversion mania seems to be dying down, but med tech merger mania continues. In the latest development, Becton Dickinson announced over the weekend that it will acquire Carefusion for $12.2 billion in a bid to save costs and broaden the company's offerings to hospitals. 

WuXi snags a stateside CRO to beef up its early-stage services

Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.

Parexel buys a U.K. tech outfit to expand its eClinical biz

Parexel International has bought up the U.K.'s ClinIntel, a supply chain software outfit that should fit right in with the CRO's growing technology business.

EU green-lights Novartis sale of its animal health business to Eli Lilly

European Union regulators approved the sale of Novartis' animal health business to Eli Lilly in a deal worth $5.4 billion that is expected to propel the U.S. drugmaker closer to the front of the veterinary products line.

Alere close to sale of health management unit

Alere management is in advanced talks to sell its health management business, according to Reuters. In August, the diagnostics player had said it would do so before year-end as part of an ongoing strategic review aimed at returning the company to revenue and earnings growth.

Report: Arbor Pharma goes on the block for $1B-plus

Private drugmaker Arbor Pharmaceuticals is looking for a buyer, according to Reuters, going on the market with a price tag that could exceed $1 billion.

Add Arbor Pharma to your shopping list: It's on the block for $1B-plus

It's a good time to be a specialty drugmaker--especially one looking to sell itself. And that's the position Arbor Pharmaceuticals is reportedly in right now.

Medtronic undeterred by new regs, to finance acquisition of Covidien with external funds

Medtronic announced that it will fund its $43 billion acquisition of Ireland's Covidien using $16 billion in external financing instead of capital from its foreign subsidiaries. The tweak is in response to Treasury Department rules designed to discourage inversions.

Salix drops Cosmo buy, opting to talk takeover with Actavis

Chalk up a victory for the U.S. Treasury Department, whose new rules put the kibosh on Salix Pharmaceuticals' tax inversion deal for Cosmo's Irish unit. Instead, the North Carolina company is reportedly in talks to sell itself--but to Actavis, not Allergan.